Healthcare | August 08, 2021
Metropolis Healthcare PAT at Rs 74.89 crores for Q1FY22
Board approves fundraise of Rs 1500 crore
Board approves fundraise of Rs 1500 crore
The transaction is expected to close in the Q4FY22
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Turnover of API division of ISLL stood at Rs 856.58 crore
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC
The company has already embarked upon significant expansion in Turkey
Subscribe To Our Newsletter & Stay Updated
